Archives
-
Marein Restores Topotecan Sensitivity via ABCG2
2026-10-07
A 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the drug-efflux transporter ABCG2. The findings suggest that marein can increase intracellular exposure to ABCG2-substrate chemotherapeutics, including Topotecan, although the evidence remains preclinical and does not establish clinical combination efficacy.
-
Forsythoside E and PKM2: A Translational Lens
2026-10-07
Forsythoside E is emerging as a mechanism-defined probe of macrophage immunometabolism. By promoting PKM2 tetramerization at K311, the compound links glycolytic restraint, mitochondrial recovery, STAT3 phosphorylation suppression, and macrophage-state remodeling in a mouse model of sepsis-induced liver injury. This article examines the evidence, translational boundaries, competitive positioning, and research questions that matter beyond a conventional product description.
-
p-Cresyl Sulfate in CKD Cardiovascular Research
2026-10-06
p-Cresyl sulfate, also known as p-tolyl hydrogen sulfate, is a protein-bound uremic solute studied in chronic kidney disease and cardiovascular complications. This overview examines its proposed relationship with endothelial dysfunction and calcific aortic valve disease, emphasizing findings from a 2026 porcine-cell and rat-model study. The evidence supports a mechanistic association between p-Cresyl sulfate exposure, klotho/SIRT1 signaling, inflammatory transcriptional responses, and valvular calcification, but does not establish human causality or a clinical treatment strategy. Important limitations include model dependence, uncertainty about clinically representative exposure, and the absence of direct evidence that modifying this pathway improves patient outcomes.
-
GLP-1R Cross-Talk Revealed by cAMP FRET
2026-10-06
Chepurny and colleagues showed that glucagon can activate the GLP-1 receptor under defined assay conditions, challenging the assumption that glucagon and GLP-1 receptor pharmacology is strictly selective. Their FRET-based cAMP measurements, molecular modeling, and cell validation also revealed context-dependent antagonist activity and supported a broader framework for interpreting receptor cross-talk in metabolic research.
-
Bestatin (Ubenimex): From Inhibition to Translation
2026-10-05
Bestatin, also known as Ubenimex, is more than a catalog aminopeptidase inhibitor: it is a mechanistic probe whose value depends on how carefully target engagement is separated from downstream phenotype. This thought-leadership perspective connects aminopeptidase biology, chemical genetics, multidrug resistance research, and translational decision-making while defining the boundaries of the available evidence.
-
Losartan: AT1 Blockade in Hypertension Research
2026-10-05
Losartan is an angiotensin II receptor antagonist used to study AT1-dependent vascular signaling and hypertension biology. Product-level evidence supports receptor antagonism and vascular smooth muscle cell proliferation inhibition, while recent tumor research provides class-level evidence for ARB effects on collagen-rich tumor microenvironments.
-
Catalpol in Alzheimer’s Disease: Evidence and Mechanisms
2026-10-04
The 2022 review synthesizes preclinical evidence that catalpol may protect against Alzheimer’s disease through anti-inflammatory, antioxidant, antiapoptotic, and broader neuroprotective effects. Its main contribution is an integrated mechanistic framework, while its clinical implications remain limited by the heterogeneity and largely preclinical nature of the underlying evidence.
-
Candida krusei Apoptosis Pathways in BMECs
2026-10-03
Miao et al. show that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but with different pathway signatures. The study connects yeast-associated injury primarily with mitochondrial signaling and hypha-associated injury with death ligand/receptor signaling, while implicating TLR2/ERK and JNK/ERK regulation.
-
Catalpol in Alzheimer’s Disease: Mechanisms and Evidence
2026-10-02
The reference review synthesizes evidence that catalpol, an iridoid glycoside from Rehmannia glutinosa, may counter several Alzheimer’s disease-related processes, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Its main contribution is a mechanistic framework for interpreting preclinical findings, while also highlighting the need for better dose, model, pharmacokinetic, and clinical validation.
-
Cell lysis buffer for WB and IP: CAF Workflows
2026-10-01
Build cleaner Western blot and co-immunoprecipitation workflows for studying CAF-driven chemoresistance, phosphorylation, and protein interactions. This guide combines a non-denaturing extraction strategy with practical controls for ANGPTL4–IQGAP1 pathway research and difficult tissue samples.
-
p-Cresyl Sulfate: Bench Workflows for CKD Models
2026-10-01
Build reproducible p-Cresyl sulfate assays for endothelial dysfunction, wound repair, uremic toxin clearance, and hepatobiliary injury research. This workflow combines protein-binding controls, fresh-solution handling, and the latest biliary epithelial cell findings to separate cytotoxicity from disease-relevant signaling.
-
p-Cresyl Sulfate: From Signal to Strategy
2026-09-30
p-Cresyl sulfate is more than a retained uremic metabolite: it is a translational tool for connecting renal dysfunction, endothelial repair, inflammation, and tissue-specific injury. This thought-leadership guide integrates vascular assay design with emerging hepatobiliary evidence, emphasizing albumin context, renal clearance, experimental controls, and opportunities for biomarker and intervention research.
-
PF-573228 Workflows for FAK Signaling
2026-09-30
PF-573228 is a practical FAK inhibitor for connecting phosphorylation changes with cancer-cell behavior, ferroptosis biology, and endothelial responses. This workflow emphasizes matched target-engagement and phenotype assays so researchers can distinguish pathway-specific effects from nonspecific toxicity.
-
Candida krusei Forms Trigger Distinct BMEC Apoptosis
2026-09-29
The reference study shows that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but rely predominantly on different signaling routes. Its co-culture, imaging, flow-cytometry, mitochondrial, TUNEL, and immunoblotting framework provides a useful model for separating morphology-specific host-cell responses during fungal mastitis.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-09-29
The reference study identifies SmD2 acetylation as a regulatory connection between core spliceosome function, BRCA1/FANC cassette-exon usage, and DNA-damage repair in hepatocellular carcinoma. Its combination of Romidepsin and Olaparib in HCC models provides a mechanistic rationale for testing HDAC-directed and PARP-directed treatment together, while also defining important limits for translation.